Glioblastoma is the most common yet most lethal of primary brain cancers with a one-year
post-diagnosis survival rate of 65% and a five-year survival rate of barely 5%. Recently the …

Simple Summary The FDA recently approved a fourth approach (in addition to surgery,
radiation therapy, and chemotherapy) for treating glioblastoma; namely, tumor treating fields …

Despite major advances in therapy, cancer continues to be a leading cause of mortality. In
addition, toxicities of traditional therapies pose a significant challenge to tolerability and …

Simple Summary Glioblastoma (GBM) is the most common malignant primary brain tumor.
Although the standard of care, including maximal resection, concurrent radiotherapy with …

Tumor treating fields (TTFields) is a noninvasive, regional antimitotic treatment modality that
has been approved for the treatment of recurrent glioblastoma by the US FDA and has a CE …

Importance Tumor-treating fields (TTFields) is an antimitotic treatment modality that
interferes with glioblastoma cell division and organelle assembly by delivering low-intensity …

Introduction: Local control is fundamental, both for the curative as well as the palliative
treatment of cancer. Tumor treating fields (TTFields) are low intensity (1–2 V/cm) …

As with many cancer treatments, tumor treating fields (TTFields) target rapidly dividing tumor
cells. During mitosis, TTFields-exposed cells exhibit uncontrolled membrane blebbing at the …

Abstract Tumor Treating Fields (TTFields), a new modality of cancer treatment, are electric
fields transmitted transdermally to tumors. The FDA has approved TTFields for the treatment …

The standard of care for patients with newly diagnosed Glioblastoma multiforme (GBM) has
remained unchanged since 2005, with patients undergoing maximal surgical resection …